KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other financing activities (2020 - 2025)

Historic Other financing activities for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $3.0 million.

  • Royalty Pharma's Other financing activities rose 90666.67% to $3.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $20.0 million, marking a year-over-year increase of 30030.1%. This contributed to the annual value of $16.6 million for FY2025, which is 3128.57% up from last year.
  • Latest data reveals that Royalty Pharma reported Other financing activities of $3.0 million as of Q4 2025, which was up 90666.67% from $13.5 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Other financing activities ranged from a high of $13.5 million in Q3 2025 and a low of $300000.0 during Q4 2024
  • Moreover, its 5-year median value for Other financing activities was $2.3 million (2023), whereas its average is $4.5 million.
  • Per our database at Business Quant, Royalty Pharma's Other financing activities tumbled by 8120.3% in 2024 and then skyrocketed by 90666.67% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Other financing activities stood at $801000.0 in 2021, then surged by 68.16% to $1.3 million in 2022, then rose by 18.49% to $1.6 million in 2023, then tumbled by 81.2% to $300000.0 in 2024, then soared by 906.67% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q4 2025, $13.5 million for Q3 2025, and $300000.0 during Q4 2024.